Please use this identifier to cite or link to this item:
Title: Pharmacogenetic testing for personalisation of statin therapy
Authors: Cerdá Iñesta, Judith
Wirth, Francesca
Mifsud Buhagiar, Luana
Zahra, Graziella
Xuereb, Robert G.
Barbara, Christopher
Serracino-Inglott, Anthony
Keywords: Statins (Cardiovascular agents) -- Research -- Malta
Statins (Cardiovascular agents) -- Side effects
Personalized medicine
Muscles -- Diseases
Hospital pharmacies
Issue Date: 2019-03
Publisher: University of Malta. Department of Pharmacy
Citation: Cerda Inesta, J., Wirth, F., Mifsud Buhagiar, L., Zahra, G., Xuereb, R. G., Barbara, C., & Serracino-Inglott, A. (2019, March). Pharmacogenetic testing for personalisation of statin therapy. Poster session presented at the 24th Congress of the European Association of Hospital Pharmacists (EAHP), Barcelona, Spain.
Abstract: A poster presentation regarding pharmacogenetic testing for personalisation of statin therapy. Introduction: The SLCO1B1 protein facilitates the hepatic uptake of simvastatin. The SLCO1B1 c.521T>C genetic polymorphism (rs4149056) decreases the function of SLCO1B1 and is a predictor of simvastatin-induced myopathy. SLCO1B1 pharmacogenetic testing and pharmacist interpretation of test results are a step forward to personalise statin therapy. Aims: • To classify a cohort of cardiac patients on simvastatin according to SLCO1B1 c.521T>C genotype and function • To investigate the correlation of SLCO1B1 genotype and function to myopathy risk.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Pharmacogenetic_testing_for_personalisation_of_statin_therapy_2019.pdf995.51 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.